Ver­tex CEO to UK Prime Min­is­ter: You’re de­valu­ing lives, pass­ing up a great of­fer and threat­en­ing the coun­try’s biotech in­dus­try

Ver­tex has scored big in the US with its new drugs for cys­tic fi­bro­sis, but the biotech still has to slug it out for every inch of mar­ket ter­ri­to­ry in Eu­rope — where its price for Orkam­bi is of­ten seen as way too high for the val­ue it of­fers. And af­ter get­ting snubbed in the UK last week — again — af­ter a long-run­ning cam­paign to win a re­im­burse­ment deal from the NHS, CEO Jef­frey Lei­den has de­cid­ed to pub­licly chas­tise British Prime Min­is­ter There­sa May for the stand­off.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.